
Lori Reilly Lori M. Reilly is Chief Operating Officer, providing executive level management, leadership and strategic direction at the Pharmaceutical Research and Manufacturers of America (PhRMA). In this role, Ms. Reilly oversees PhRMA’s Advocacy activities, including its federal, state, and international government affairs and alliance development work. Ms. Reilly provides strategic leadership and works across PhRMA to develop and advocate for practical policy solutions that will lower costs for patients. Ms. Reilly, named by the Hill as a top lobbyist in 2018, has a long record of working with members of Congress on a bipartisan basis and collaborating with stakeholders across the health care industry. Ms. Reilly is a frequent presenter on industry-related issues, including testifying before Congress on multiple occasions. Ms. Reilly has nearly two decades of experience at PhRMA; prior to her current role, Ms. Reilly was the Executive Vice President of Policy, Research, and Membership at PhRMA, leading the development and implementation of legislative, regulatory, and political strategies to advance policies that encourage patient access and medical innovation. She has also served as counsel at the U.S. House of Representatives Committee on Commerce and was Counsel to a member of the House Ways and Means Committee. Ms. Reilly received a B.A. in Political Science from the University of Nebraska-Lincoln where she graduated with Honors, and a J.D. from the University of Nebraska College of Law. She is currently resides in Alexandria, Virginia with her husband and their four children.
Recent Posts
ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress

Report: More than 600 medicines in development for diseases affecting women

In combating COVID-19, science is how we get back to normal

PhRMA awards $100,000 to fund projects that address health inequalities

Event: New era of medicine comes to Capitol Hill

Putting 2014 Figures on Prescription Drug Spending in Context

Which 340B Entities Are Getting Most of the Savings?
